The French INSERM, or Institut National de la Santé et de la Recherche Médicale (French National Institute of Health and Medical Research) is the only public sector research institution in France, exclusively dedicated to human health. Since its creation in 1964 has played a part in many key, historic medical advances including the first in skin grafting and gene therapy and counts several NOBEL and LASKER Prizes in Medicine. INSERM is the leading academic biomedical research institution in Europe with some 12,000 publications a year; it is only second in the world to the American National Institutes of Health.
INSERM operates under the dual aegis of the Ministry of Health and the Ministry of Research. INSERM. It boasts a wide range of facilities, taking a multidisciplinary, reactive and integrated approach to biomedical research. The institution boasts 365 research units across France and Internationally, in the main fields of biomedical and health research, and is run by 6,500 permanent staff members. Among them are Professor Robert BALLOTTI director of U1065 and Dr. Céline Gaudel, the latter being a doctor in molecular biology. Both are involved in an ambitious fundamental research program with NUNII.
The partnership NUNII has developed with INSERM is of private-public nature, making it particularly dynamic in that the funding is mostly provided by NUNII itself regarding the sector of dermo-cosmetics. In return, INSERM brings its invaluable know-how, which has been developed over the past decades. The success of this partnership is based on sharing skills, opening up to talent and staying close to patients.
The NUNII-INSERM partnership is of specific importance to both parties, as very little other fundamental research and true innovation has been conducted in the industry of dermo-cosmetics in the world to date in the treatment of pigmentation disorders.
The quality of the partnership has enabled the teams to push the boundaries in the current knowledge regarding melano-genesis. More specifically, the 2 entities have been combining their efforts to map the human genome section responsible for skin pigmentation synthesis. The idea behind the research being to better understand and identify new key factors involved the pigmentation process.
With such findings, the teams will be well-positioned to use the new knowledge gained, to access the effectiveness of new molecules to be used in exclusively patented NUNII skin treatment products in the years to come. Another benefit of this research will be to identify and exclude potentially toxic ingredients to ensure that they are excluded from NUNII products, thus guaranteeing doctors and patients an even higher level of safety.
The NUNII-INSERM partnership is the promise of great prospects for NUNII product users. This partnership fits perfectly with the NUNII ethos and values of passion, integrity and a commitment to excellence in product safety and continuous innovation based on solid scientific research.